You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):ASC09複方片聯合α-干擾素霧化治療新型冠狀病毒肺炎臨牀研究獲批
格隆匯 02-13 12:32

格隆匯2月13日丨歌禮制藥-B(01672.HK)公佈,由重慶醫科大學附屬第二醫院胡鵬教授團隊發起的ASC09複方片聯合α-干擾素霧化治療新型冠狀病毒肺炎臨牀研究獲重慶醫科大學附屬第二醫院倫理委員會批准。公告顯示,胡鵬教授是重慶醫科大學附屬第二醫院感染科主任,重慶市醫學會肝病學專業委員會主任委員。

截至公告日期,ASC09複方片已獲得武漢同濟醫院、浙江大學醫學院附屬第一醫院和重慶醫科大學附屬第二醫院等批准開展治療新型冠狀病毒肺炎臨牀研究。

英國「自然」雜誌於2020年2月10日發表的《Therapeutic options for the 2019 novel coronavirus (2019-nCoV)》一文收錄了ASC09複方片和利托那韋用於治療新型冠狀病毒肺炎的臨牀研究。人民日報社人民網亦於2020年2月11日報道了關於武漢同濟醫院寧琴教授團隊發起的ASC09複方片和利托那韋治療新型冠狀病毒肺炎的臨牀研究。

公告稱,公司目前具有充足的ASC09複方片及利托那韋生產能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account